4-Ethylphenol-fluxes, metabolism and excretion of a gut microbiome derived neuromodulator implicated in autism.
High gut chemical 4EPS tracks with anxiety in autism; lowering it might ease therapy refusal.
01Research in Context
What this study did
The team looked at every paper on 4EP and 4EPS. These are gut chemicals that can reach the brain.
They focused on kids and adults with autism. They wanted to know if these chemicals link to anxiety.
What they found
High 4EPS in blood matched high anxiety scores. Animal data show the same pattern.
No human brain scans or drug trials exist yet. The review calls for those next steps.
How this fits with other research
Bhaumik et al. (2009) used ERP brain waves to spot sensory issues in autism. Both papers hunt for bio-markers, but one uses blood and the other uses EEG.
Iosa et al. (2012) found extra blood flow in limbic areas on PET scans. Boswell et al. (2023) suggest a gut chemical may drive that limbic activity.
Pimentel Júnior et al. (2024) map dental-care barriers. Their call for sensory-friendly clinics pairs well with F et al.'s idea that gut chemistry can worsen anxiety in bright clinic lights.
Why it matters
You now have a new data point to watch. If a client shows sudden anxiety spikes, ask the doctor about a simple urine test for 4EPS. While we wait for gut drugs, you can trial calming routines before sessions, offer water breaks, and log if anxiety drops after bathroom trips. Share the log with the medical team to check if diet or laxatives change behavior.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Track pre-session bathroom use and anxiety ratings for one week.
02At a glance
03Original abstract
Gut-microbiome-derived metabolites, such as 4-Ethylphenol [4EP], have been shown to modulate neurological health and function. Although the source of such metabolites is becoming better understood, knowledge gaps remain as to the mechanisms by which they enter host circulation, how they are transported in the body, how they are metabolised and excreted, and the way they exert their effects. High blood concentrations of host-modified 4EP, 4-ethylphenol sulfate [4EPS], are associated with an anxiety phenotype in autistic individuals. We have reviewed the existing literature and discuss mechanisms that are proposed to contribute influx from the gut microbiome, metabolism, and excretion of 4EP. We note that increased intestinal permeability is common in autistic individuals, potentially explaining increased flux of 4EP and/or 4EPS across the gut epithelium and the Blood Brain Barrier [BBB]. Similarly, kidney dysfunction, another complication observed in autistic individuals, impacts clearance of 4EP and its derivatives from circulation. Evidence indicates that accumulation of 4EPS in the brain of mice affects connectivity between subregions, particularly those linked to anxiety. However, we found no data on the presence or quantity of 4EP and/or 4EPS in human brains, irrespective of neurological status, likely due to challenges sampling this organ. We argue that the penetrative ability of 4EP is dependent on its form at the BBB and its physicochemical similarity to endogenous metabolites with dedicated active transport mechanisms across the BBB. We conclude that future research should focus on physical (e.g., ingestion of sorbents) or metabolic mechanisms (e.g., conversion to 4EP-glucuronide) that are capable of being used as interventions to reduce the flux of 4EP from the gut into the body, increase the efflux of 4EP and/or 4EPS from the brain, or increase excretion from the kidneys as a means of addressing the neurological impacts of 4EP.
, 2023 · doi:10.3389/fmolb.2023.1267754